An FTI Consulting survey puts GLP-1 use at 18% of U.S. adults, up from 14% a year earlier. Smoothie King has built the first official GLP-1 menu at a national restaurant chain, led by a 45 gram protein smoothie and a 23 gram protein, 9 gram fiber pumpkin option, while Old Spaghetti Factory has sold…
Roughly 18% of U.S. adults now take a GLP-1 medication, up from 14% a year earlier, according to a survey by FTI Consulting. A four-point rise across twelve months is a substantial move for a drug class that barely registered in consumer conversation a decade ago. Unnamed projections put the figure as high as 30% of Americans by the end of the decade. If that trajectory holds, the treated population will be far larger than the combined enrollment of every registered semaglutide trial on file, and those people will be expressing their appetite suppression in restaurants rather than in protocol visits.
Restaurant operators are not waiting for that forecast to resolve. Smoothie King built the first official GLP-1 menu at a national restaurant chain. Old Spaghetti Factory, a 40-unit chain, launched a smaller-portion Great Little Plate menu. Technomic, the foodservice data firm, expects GLP-1 drugs to cost the restaurant industry 0.5% to 0.7% of sales by 2030.
The more useful number for operators is not the size of that hit but its location. Analysts and operators describe a change in order composition rather than visit frequency. Diners on these peptides still come through the door. They order smaller portions of indulgent items, more protein and fewer combo meals. Technomic expects the losses to concentrate in portion sizes, appetizers and desserts rather than in visit occasions. Roughly one out of five potential restaurant customers is actively cutting back on how much they eat, which is the same signal read from the demand side.
That distinction governs everything downstream. If the industry were losing covers, the response would be pricing, promotions and delivery. Because it is losing items per cover, the response is menu architecture: smaller plates, higher protein density, fewer bundled combinations, and a hard look at the appetizer and dessert sections that historically carried the best margins. A 0.5% to 0.7% sales impact sounds small until it is mapped onto the specific line items where it lands.
The arithmetic behind that forecast deserves stating plainly. Half a percent to seven-tenths of a percent is a thin slice of total industry revenue, but restaurant operating margins are themselves thin, and a reduction concentrated in appetizers and desserts removes the items with the highest contribution margin per unit of menu space. Those categories also generate the least incremental labor and the most incremental check. A diner who skips them does not reduce the restaurant's rent, insurance or kitchen staffing by a penny. The asymmetry between where the revenue disappears and where the costs sit is what makes a sub-1% forecast matter more than its headline size suggests. It also explains why the two chains that moved first did not launch discounts or quietly shrink portions. They launched named menus.
Smoothie King's line is specified down to the gram. The Gladiator Protein Strawberry carries 45 grams of protein and 220 calories. The Slim-N-Trim GLP-1 Pumpkin smoothie carries 23 grams of protein and 9 grams of fiber with no added sugar, part of a pumpkin-flavored smoothie line the chain rolled out for the season. The company developed the GLP-1 line with a nutritional expert to hit targeted fiber and protein levels, a formulation brief that reads like a clinical nutrition specification rather than a beverage marketing brief.
The commercial result shows up on the loyalty file. More than 500,000 Smoothie King loyalty program members have ordered a GLP-1 menu item, a 27% year-over-year increase. Claudia Schaefer, chief marketing officer for Smoothie King, described the trigger: "We saw that these GLP-1 medications were starting to make inroads. Consumers were talking about that. Our guests were looking for solutions."
Old Spaghetti Factory took a quieter route. Its Great Little Plate menu debuted in June with smaller portions, and more than 50,000 of those meals have sold since. The Garlic Alfredo Sauce and Shrimp plate is the clear favorite, ahead of the Marinara Sauce and Meatballs plate. Nick Underwood, director of brand innovation at Old Spaghetti Factory, said the branding nods at GLP-1 users without being restricted to them: "We didn't really want to flat-out just be marketing to GLP-1 users. We wanted something on our menu for people on that medication."
The two chains are solving different problems, which is why their numbers are not comparable. A beverage platform can reformulate at the blender: swap the base, change the sweetener, add fiber, adjust the protein scoop, and the product changes without touching the kitchen line or the price architecture. A full-service pasta concept cannot do that. Reducing a plate means changing portion size, food cost, plate presentation and the customer's perception of value all at once, which is why the Great Little Plate is a distinct menu item with its own name rather than a silent reduction on the standard entree. Underwood's phrasing reflects that constraint: a named small plate can serve a GLP-1 user, a lighter appetite, an older diner and a budget-conscious guest with the same product.
Neither company's figures have been independently audited, and full-year sales and store counts are not disclosed, which makes the two data points hard to normalize. A half million loyalty members ordering from one menu line means something very different at a chain with three million members than at one with thirty million. The same applies to 50,000 plates across 40 units: roughly 1,250 plates per restaurant since June, a rate that is real but modest against total covers. What the numbers do establish is direction. Both chains built the product before the demand was fully measurable, and both report the response was faster than planned. The 27% year-over-year increase in loyalty members ordering from the GLP-1 line is the more instructive of the two figures, because it measures growth in a defined population rather than a cumulative count with an unknown denominator.
The adoption headline comes from a survey of U.S. adults by FTI Consulting. The finding: 18% reported taking a GLP-1 medication, against 14% a year earlier. That design is well suited to tracking prevalence over time and poorly suited to explaining why any individual restaurant's traffic changed.
Several design details are not public. Sample size, methodology, field dates and margin of error are all undisclosed. Without a margin of error, the four-point gap between 14% and 18% cannot be tested for statistical significance, though a swing of that size across a full year makes sampling noise an unlikely sole explanation. At the same time, a single unweighted survey wave of a few thousand respondents can carry a margin of error wide enough that part of the movement sits inside the noise band. The only way to know is to publish the interval. The survey also does not separate semaglutide from other GLP-1 receptor agonists, does not capture dose or treatment duration, and does not distinguish diabetes from weight-loss indications. Those omissions matter for interpretation: a patient on a stable maintenance dose for weight loss and a patient on a diabetes regimen have different appetites, different daily routines and different restaurant behavior.
Causality is the harder problem. Experts have tied GLP-1 use to weak restaurant industry sales, but no causal evidence connects the two, and the link is described as hard to argue against rather than demonstrated. Consumer spending pressure, menu price inflation and a shift toward eating at home all moved in the same direction over the same period. Technomic's 0.5% to 0.7% sales impact is itself a forecast rather than measured data, built from assumptions about adoption, per-visit spend and how much of the reduced spend stays in the category rather than migrating to groceries.
The design that would settle the question is not exotic. Adoption varies by geography, by income band and by insurer, and those gradients create natural comparisons: item-level transaction data from markets with high versus low GLP-1 penetration, read against the same period a year earlier, would separate drug effects from macro spending effects. Repeated survey waves with published methodology would let analysts watch the trend rather than infer it. Item-level data has the further advantage of being immune to the recall problem that limits any self-reported survey: respondents are asked whether they take a medication, not to reconstruct what they ordered six weeks ago. Until those comparisons exist, the honest statement is that prevalence is rising fast, industry sales are soft, and the two facts are consistent with each other without being proven to be connected.
The molecule at the center of this sits on peptide chemistry that predates the menu changes by nearly four decades. In 1987, Joel Habener , an endocrinologist and researcher at Harvard University, discovered a gut molecule that signals the pancreas to produce insulin while working on anglerfish. That line of work on the glucagon gene family identified what became known as glucagon-like peptide 1, a hormone that had no pharmaceutical use for years because it is destroyed in the bloodstream within minutes of release.
The reason for that short life is enzymatic. Native GLP-1 is cleaved by dipeptidyl peptidase-4, an enzyme that circulates widely and trims the peptide before it can act for long. A hormone that survives for two minutes is not a drug. Making it one required structural changes that resist that cleavage and extend the circulating half-life from minutes to days, which is what turned an intestinal signal into a weekly injection. The first GLP-1 medication to treat diabetes was created in 2005.
Translation took time. Sixteen years separated that first diabetes medication, created in 2005, from the U.S. Food and Drug Administration 's approval of semaglutide , the active ingredient in Wegovy and Ozempic , for weight loss, which came around 2021. Sixteen years is the interval between a drug that lowers blood sugar in people with diabetes and a drug that is prescribed to people who do not have diabetes at all, and the length of that interval reflects how much harder the second indication is to earn. Regulators require durable weight reduction, a safety profile tolerable in a population treated for years without acute illness, and evidence on cardiovascular and metabolic outcomes. Demonstrating glycemic control is a smaller evidentiary ask than demonstrating that a chronic therapy is worth taking indefinitely by people who feel well.
That approval is the regulatory hinge for the consumer market now visible in restaurant sales data. The FDA's action covers a weight-loss indication for semaglutide and binds the drug's sponsors: it governs labeling and promotion, not what restaurants serve or how clinicians prescribe. Prescribing outside an approved indication remains a clinician's judgment, and nothing in the approval addresses diet composition, meal timing or portion size. Mounjaro is a separate agent with its own approval and labeling, and it acts on more than one incretin receptor, which is one reason its clinical profile is not interchangeable with semaglutide's. A consumer survey that groups all of these molecules under a single question about GLP-1 use is therefore measuring a pharmacological average, not a defined exposure.
GLP-1 is an incretin hormone released by enteroendocrine L-cells in the distal small intestine in response to nutrients. It amplifies insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric…
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, GLP-1.
Related reading: HelloFresh Ends Week at EUR 2.801 After 2.88 Percent Drop, Updated review ranks tirzepatide top among GLP-1 weight-loss agents, Employers Drop GLP-1 Weight-Loss Coverage as Costs Climb and Use Rises, Combination therapy, not stronger GLP-1s, will define obesity care.